



Joint Symposium BIOCON-KI

Nobel Forum

April 25th 2014, 9.00-16.30

Tentative programme:

09.00-09.10	Opening words, Klas Wiman
09.10-09.20	Welcoming remarks, Ambassador of Korea
09.20-09.40	Sunghoon Kim , Director of Biocon Project, Seoul National University <i>Biocon: Integrated Research Platform for Target Discovery</i>
09.40-10.00	Galina Selivanova , KI, Dept. of Microbiology, Tumor and Cell Biology <i>Targeting p53/MDM2 interaction to combat cancer</i>
10.00-10.20	Young Ho Jeon , Korea University <i>Lysyl-tRNA Synthetase (KRS) in the Control of Laminin Signaling and Cancer Metastasis</i>
10.20-10.50	Coffee
10.50-11.10	Sten Nilsson , KI, Dept. of Onkology-Pathology <i>Radium-223 for treatment of bone metastatic prostate cancer</i>
11.10-11.30	Jung Min Han , Yonsei University <i>Leucyl-tRNA Synthetase as Novel mTOR Regulator and Its Functional Implication in Cancer</i>
11.30-11.50	Thomas Helleday , KI, Dept. of Medical Biochemistry and Biophysics <i>From PARP to MTH1 inhibitors: towards depersonalized anti-cancer treatment</i>
11.50-12.10	Nam Hoon Kwon , Seoul National University, Biocon <i>Implication of Methionyl-tRNA Synthetase for Cell Proliferation and Cancer</i>
12.10-13.10	Lunch break
13.10-13.20	Sonia Lain , KI, Dept. of Microbiology, Tumor and Cell Biology <i>MJ05, a new family of potential small molecule cancer therapeutics</i>
13.30-13.50	Ho Lee , National Cancer Center <i>AIMP3: A Master Regulator of Cancer, Aging and Stem Cells</i>
13.50-14.10	Lars-Gunnar Larsson , KI, Dept. of Microbiology, Tumor and Cell Biology <i>Targeting the Myc oncoprotein</i>
14.10-14.30	Pilhan Kim , Korea Advances Institute of Science and Technology <i>Intravital Microscopy for Cancer Imaging</i>
14.30-15.00	Coffee
14.00-15.20	Marie Arsenian-Henriksson , KI, Dept. of Microbiology, Tumor and Cell Biology <i>MYCN and differentiation control in neuroblastoma</i>
15.20-15.40	Jiho Park , Korea Advances Institute of Science and Technology <i>Engineering Drug Delivery to Improve Cancer Therapy</i>
15.40-16.00	Stig Linder , KI, Dept. of Onkology-Pathology <i>Inhibition of proteasome deubiquitinating activity as a novel cancer therapy</i>
15.00-16.20	Klas Wiman , KI, Dept. of Onkology-Pathology <i>Mutant p53 reactivation by Michael addition – molecular mechanisms and clinical results</i>
16.20-16.30	Closing remarks, Klas Wiman